NasdaqGM:ARDXBiotechs
How IBSRELA Trial Expansion And New 2042 Patent At Ardelyx (ARDX) Has Changed Its Investment Story
Ardelyx recently announced dosing of the first patient in ACCEL, a Phase 3 trial of IBSRELA (tenapanor) in adults with chronic idiopathic constipation, while also securing a new U.S. patent extending oral formulation protection for IBSRELA and XPHOZAH to 2042.
The combination of advancing IBSRELA into a large new indication and lengthening patent protection may reshape how long Ardelyx’s medicines can remain differentiated in the market.
With the new 2042 formulation patent as a backdrop,...